Company Fundamentals\Company Profile
A Wright Investors' Service Research Report:
Shire PLC
440 Wheelers Farms Road
Milford, CT 06461 U.S.A.
COMPANY PROFILE
Figures in Pounds Sterling
Wright Quality Rating:AAB17 Key Data
Shire plc (Shire)is a specialty biopharmaceutical company that focuses on meeting Ticker:
the needs of the specialist physician. Shire focuses its business on attention deficit SHP
hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal
(GI) diseases. AS of December 31, 2010, the Company's products include VYVANSE, 2010 Sales:
INTUNIV, EQUASYM (methylphenidate hydrochloride), ADDERALL XR (mixed salts of a
2,239,414,876
single-entity amphetamine) for treatments of ADHD; LIALDA (mesalamine)/
MEZAVANT(mesalazine), PENTASA (mesalamine) and RESOLOR (prucalopride) for
treatment of GI diseases; FOSRENOL (lanthanum carbonate), CALCICHEW (calcium Major Industry:
carbonate range), CARBATROL (carbamazepine extended-release capsules) and Drugs, Cosmetics & Health
XAGRID (anagrelide hydrochloride) for treatment of diseases in other therapeutic Care
areas, and REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), FIRAZYR (icatibant)
and VPRIV (velaglucerase alfa) for treatment of HGT. Shire launched VYVANSE in Sub Industry:
Canada in February 2010. Ethical Drug Manufacturers
Stock Chart Officers
Non Executive Chairman Country:
Matthew W. Emmens United Kingdom
Executive Director & Chief Currency:
Executive
Pounds Sterling
Angus Charles Russell
Fiscal Year Ends:
Chief Financial Officer
Graham Hetherington December
Secretary & General Counsel Employees
Tatjana May 4,183
Exchanges: